Abstract
Multidrug resistance (MDR) due to overexpression of MDR1 is a major obstacle that hinders the treatment of hepatocellular carcinoma (HCC). In this study, we explored the function and underlying molecular mechanism of SIRT6 in MDR of HCC. Chemotherapeutic agents (doxorubicin, cisplatin, and sorafenib) treatment increased SIRT6 mRNA and protein level in two HCC cell lines in a dose-dependent manner. SIRT6 depletion resulted in decreased cell viability and increased apoptosis in HCC cells treated with chemotherapeutic agents. Mechanistically, SIRT6 depletion reduced MDR1 transcription by targeting its promoter in HCC cells treated with chemotherapeutic agents. Consistently, the protein level of MDR1 was also reduced in SIRT6-depleted HCC cells. Further studies indicated that SIRT6 depletion may suppress CCAAT/enhancer binding protein β (C/EBPβ), to act as a transcriptional activator of MDR1 in HCC cells treated with chemotherapeutic agents. Importantly, forced expression of MDR1 could attenuate the apoptosis induced by chemotherapeutic agents in SIRT6-depleted cells. Taken together, these results indicated SIRT6 depletion enhanced chemosensitivity of human hepatoma cells by downregulating MDR1 expression through suppressing C/EBPβ. SIRT6 may serve as a novel target to enhance chemosensitivity in HCC cells.
Highlights
Hepatocellular carcinoma (HCC) is one of the most common and third-leading causes of cancer deaths worldwide (El-Serag and Rudolph, 2007)
The results showed the mRNA level of MDR1 was markedly downregulated in SIRT6depleted cells under the treatment of chemotherapeutics (Figures 4A,B)
Silent information regulator 6 (SIRT6) depletion had no significant effect on the mRNA level of c-Jun and P53 in hepatocellular carcinoma (HCC) cells treated with chemotherapeutic agents (Supplementary Figures 3C,D)
Summary
Hepatocellular carcinoma (HCC) is one of the most common and third-leading causes of cancer deaths worldwide (El-Serag and Rudolph, 2007). 0.7 million of people die each year from the liver cancer (Park et al, 2008). Surgical resection is not applicable for the majority of patients who undergo metastasis or tumor recurrence. Comprehensive chemotherapy has become one of the effective treatments for the patients mentioned above. Doxorubicin and cisplatin which are cytotoxic drugs used in systemic therapy achieve low objective response rates (typically < 10%). A tyrosine kinase inhibitor sorafenib considered as a breakthrough can extend median survival by little more than a year (Stotz et al, 2015). Sorafenib has become standard therapy for advanced-stage HCC in recent years due to its good
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
